“Our number 1 ranking on the Deloitte Technology Fast 500 list reflects the dedication of our team and Vir’s executional success in bringing sotrovimab, a novel monoclonal antibody therapy, to millions of patients around the world in record time and in the midst of the COVID-19 pandemic,” said
The Company’s revenue growth between fiscal years 2018 and 2021 was fueled by global sales of sotrovimab, which were recognized in conjunction with Vir’s collaboration partner GSK, as well as additional contract, licensing and grant agreements with GSK and others, including Brii Biosciences and the
About the 2022 Deloitte Technology Fast 500™
Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies – both public and private – in
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least
Sotrovimab in
The following is a summary of information for sotrovimab. Healthcare providers in the
Sotrovimab has been authorized by the FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.
Authorized Use
On
About
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy, plans and prospects, Vir’s plans to rapidly advance a pipeline aimed at serious infectious diseases, and its expectations regarding the timing of planned data readouts from its hepatitis B, hepatitis D and influenza A development programs. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes (including the war in
Contact: MediaCarly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1-314-368-5189
Source:
2022 GlobeNewswire, Inc., source